Utilize biomarkers and imaging to identify men who have prostate cancer but low PSA levels.
Safety: To evaluate the number, frequency, duration, and relation of toxicity events to eRapa, as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v 4.03; analyzed overall and compared between dosing cohorts. Also assessed based on duration of treatment.
Endocrine therapies are commonly used to treat hormone-related cancers such as breast and prostate cancers. However, resistance to these therapies is a persistent challenge. The objective of this proposal is to understand dynamic changes of ER /AR-bound enhancers during cancer progression. The knowledge gained will increase our ability to assess therapeutic responsiveness in breast and prostate cancers.